â– LECTURE OVERVIEW: Systemic Lupus Erythematosus (SLE) is a multi-system, autoimmune disease characterized by a profound loss of self-tolerance and the production of diverse autoantibodies.
â– IMMUNOPATHOGENIC DETAILS:
1. Clearance Defects: Defective clearance of apoptotic debris exposes self-nuclear antigens to the immune system, initiating autoantibody production.
2. Core Autoantibody Profiling:
- Antinuclear Antibodies (ANA): Target nuclear antigens. Present in >95% of patients with active SLE. (High sensitivity, low specificity; standard screening test).
- Anti-dsDNA: Highly specific for SLE (>97%). Titers correlate with disease activity and the development of severe lupus nephritis.
- Anti-Smith (Sm): Highly specific for SLE (>99%). Targets small nuclear ribonucleoproteins (snRNPs); titers do not correlate with disease activity.
- Anti-Ro (SSA) and Anti-La (SSB): Associated with neonatal lupus and congenital heart block.
â– CLINICAL DIAGNOSTIC METRICS:
Establishing a definitive diagnosis requires combining serum biomarkers with gold-standard diagnostic modalities. High-sensitivity ELISAs are used initially to minimize false negatives, followed by highly specific confirmatory testing.
â– CLINICAL REGISTRY INSIGHTS:
Patient registry reviews depict high clinical validity in diverse populations, indicating highly correlated trends of symptom development and treatment responsiveness.
[HY-BOARD-1002]
🌟 Dynamic Clinical Key:
Antiphospholipid Antibodies (e.g., anti-beta-2-glycoprotein 1, anticardiolipin) are also common in SLE. Paradoxically, they prolong the in vitro partial thromboplastin time (aPTT) by interfering with phospholipids, but in vivo they cause a hypercoagulable state with recurrent arterial and venous thromboses. Always correlate elevated serum spikes with continuous vital readings to rule out false laboratory spikes. Assess demographic representation when applying trial results to real-world patients.